Sun Pharma is the India's largest drug maker, which closes to 13% and hints at a 'single -digit decline'. US generics industry is quickly changing market dynamics, increasing competitive intensity, and its customer satisfaction and they are focusing on price.
Sun Pharma invests on R&D and also investing on funding and the clinical development of global pipeline.
In the financial year 2018 the company has hinted high tax rate, and the company's march quarter was very low.
They are expecting that 15% US sales of FY18 for Sun Pharma and Taro portfolio. Sun Pharma is well positioned transition by the medium term.
For Quick Trial – 8962000225 ✔
or mail us here: email@example.com